EGFR and colorectal carcinoma: For example, frequent RAS/BRAF mutations impact on the clinical management of CRC, and it is documented that human colon cancers bearing mutated KRAS will not be responding to cetuximab (anti-EGFR monoclonal antibody) treatment.